Dr Othman Al-Sawaf joins touchONCOLOGY to discuss the CLL14 trial and the impact of venetoclax-obinutuzumab treatment on clonal growth and the potential of its use in chronic lymphocytic leukaemia. The abstract ‘Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial’ (Abstract number 127) was presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
Questions
- How is minimal residual disease used as a prognostic tool in chronic lymphocytic leukemia (CLL)?
- What were the aims and the rationale behind the CLL14 trial?
- Could you give an overview of the design of the CLL14 trial and its findings?
- How may these findings impact clinical practice?
- What are the next steps in the clinical development of CLL treatment?
Speaker Disclosures: Dr Othman Al-Sawaf has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition 2020.
